- Trials with a EudraCT protocol (2,084)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (79)

These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. |
Study title: "Amiodarone therapy in children: efficacy and side effects. - Vignati G et al. - 1985 (G. Ital. Cardiol., 15: 786-794) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Amiodarone therapy in children: efficacy and side effects. - Vignati G et al. - 1985 (G. Ital. Cardiol., 15: 786-794) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" |
Active substance: AMIODARONE |
Study summary document link (including results): |
View full study record |
Document reference: 45225 |
Study title: "Long term follow up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. - Guccione P et al. - 1990 (J. Am. Coll. Cardiol., 15: 1118-1124) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CE" "Long term follow up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. - Guccione P et al. - 1990 (J. Am. Coll. Cardiol., 15: 1118-1124) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CE" |
Active substance: AMIODARONE |
Study summary document link (including results): |
View full study record |
Document reference: 45179 |
Study title: "Optimal management o f amiodarone therapy: efficacy and side effects. - Hilleman D et al. - 1998 (Pharmacother., 18 (6 Pt 2): 138S-145S) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Optimal management o f amiodarone therapy: efficacy and side effects. - Hilleman D et al. - 1998 (Pharmacother., 18 (6 Pt 2): 138S-145S) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" |
Active substance: AMIODARONE |
Study summary document link (including results): |
View full study record |
Document reference: 45184 |
Study title: Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy |
Active substance: APIS MELIFERA-LYOPHILISED BEE VENOM |
Study summary document link (including results): |
View full study record |
Document reference: 21824 |
Study title: Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy |
Active substance: Apis mellifera / Vespula spp. |
Study summary document link (including results): |
View full study record |
Document reference: 39790 |
Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: C. Pulino Report date: 5 May 1986 Design: randomized, single-blind, comparative Objective: evaluation of efficacy and safety of ZY 15021 used with antibiotics Population: subjects with laryngo-pharyngo-tonsillar disorders Evaluations: pharyngeal pain, pain in swallowing, dysphonia, oropharyngeal inflammation; side effects Total (verum; comparator): 28 (14, 14) Age (mean, range): 13-57 years |
Active substance: BENZOXONIUM CHLORIDE/BENZOXONIUM AND LIDOCAINE |
Study summary document link (including results): |
View full study record |
Document reference: 22304 |
Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: G. Sambuco Report date: 24 Jul 1986 Design: randomized, single-blind, comparative Objective: to compare the characteristics of ZY 15021 with those of cetylpyridinium chloride Population: patients with recurrent pharyngitis-laryngitis, post-surgical oropharynx inflammation Evaluations: pharyngeal pain, difficulty swallowing, dysphonia, inflammation; side effects Age (mean, range): 12-74 years (no details provided) |
Active substance: BENZOXONIUM CHLORIDE/BENZOXONIUM AND LIDOCAINE |
Study summary document link (including results): |
View full study record |
Document reference: 22303 |
Study title: Report/protocol/study N°: Clinical study on ZY 15021 Investigator: C. Galletti Report date: 30 Apr 1986 Design: open, non comparative Objective: evaluation of therapeutic efficacy and safety of ZY 15021 gelsolets, solution, oral spray Population: subjects with laryngo-pharyngo-tonsillar disorders with throat pain Evaluations: clinical symptoms, side effectsPeloso U.C. et al.: Penicillin concentrations in sera and tonsils after intramuscolar administration of benzathine penicillin G to children. Pediat.lnfect.Dis.J. 2003;22(12):1075-8 |
Active substance: BENZENTHONIUM AND LIDOCAINE |
Study summary document link (including results): |
View full study record |
Document reference: 22284 |
Study title: Report/protocol/study N°: Clinical trial of Orofar Investigator: A. Monteverde Report date: 18 Sep 1986 Design: open, non comparative Objective: Evaluation of efficacy and safety of Orofar gelsolets Population: subjects with acute pharyngitis or tonsillitis Evaluations: body temperature, pharyngeal pain, swallowing difficulties, dysphonia, inflammation, side effects |
Active substance: BENZENTHONIUM AND LIDOCAINE |
Study summary document link (including results): |
View full study record |
Document reference: 22283 |
Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: C. Pulino Report date: 5 May 1986 Design: randomized, single-blind, comparative Objective: evaluation of efficacy and safety of ZY 15021 used with antibiotics Population: subjects with laryngo-pharyngo-tonsillar disorders Evaluations: pharyngeal pain, pain in swallowing, dysphonia, oropharyngeal inflammation; side effects |
Active substance: BENZENTHONIUM AND LIDOCAINE |
Study summary document link (including results): |
View full study record |
Document reference: 22280 |
Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: G. Sambuco Report date: 24 Jul 1986 Design: randomized, single-blind, comparative Objective: to compare the characteristics of ZY 15021 with those of cetylpyridinium chloride Population: patients with recurrent pharyngitis-laryngitis, post-surgical oropharynx inflammation Evaluations: pharyngeal pain, difficulty swallowing, dysphonia, inflammation; side effects |
Active substance: BENZENTHONIUM AND LIDOCAINE |
Study summary document link (including results): |
View full study record |
Document reference: 22279 |
Study title: Report/protocol/study N°: Clinical study on ZY 15021 Investigator: C. Galletti Report date: 30 Apr 1986 Design: open, non comparative Objective: evaluation of therapeutic efficacy and safety of ZY 15021 gelsolets, solution, oral spray Population: subjects with laryngo-pharyngo-tonsillar disorders with throat pain Evaluations: clinical symptoms, side effects Total: 26 - gelsolets: 10 subjects - solution: 9 subjects - spray: 7 subjects Age (mean, range): 6-54 year |
Active substance: BENZOYL PEROXIDE |
Study summary document link (including results): |
View full study record |
Document reference: 22308 |
Study title: Report/protocol/study N°: Clinical trial of Orofar Investigator: A. Monteverde Report date: 18 Sep 1986 Design: open, non comparative Objective: Evaluation of efficacy and safety of Orofar gelsolets Population: subjects with acute pharyngitis or tonsillitis Evaluations: body temperature, pharyngeal pain, swallowing difficulties, dysphonia, inflammation, side effects Total: 20 Age (mean, range): 13-82 years |
Active substance: BENZOYL PEROXIDE |
Study summary document link (including results): |
View full study record |
Document reference: 22307 |
Study title: Effects of anesthetic technique on side effects associated with fentanyl Oralet premedication; Journal of Clinical Anesthesia 1997, 9(5): 374-8 |
Active substance: FENTANYL |
Study summary document link (including results): |
View full study record |
Document reference: 27144 |
Study title: Determination of an effective dose of fenoterol, as free as possible from side effects for regular therapeutic use in obstructive respiratory tract diseases. |
Active substance: FENOTEROL |
Study summary document link (including results): Fenoterol hydrobromide_U83-0224_synopsis.pdf |
View full study record |
Document reference: 27087 |
Study title: Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis |
Active substance: CETIRIZINE |
Study summary document link (including results): |
View full study record |
Document reference: 23711 |
Study title: Central nervous system side effects of first- and second- generation antihistamines in school children with perennial allergic rhinitis: A randomized, double blind, placebo. Controlled comparative study |
Active substance: CHLORPHENAMINE AND PARACETAMOL |
Study summary document link (including results): |
View full study record |
Document reference: 24044 |
Study title: Side effects with use of oral transmucosal fentanyl; Pediatrics, 1995, 96(3 Pt 1): 544 |
Active substance: FENTANYL |
Study summary document link (including results): |
View full study record |
Document reference: 27181 |
Study title: Central nervous system side effects of first- and second- generation antihistamines in school children with perennial allergic rhinitis: A randomized, double blind, placebo. Controlled comparative study |
Active substance: CHLORPHENAMINE AND TRAMAZOLINE |
Study summary document link (including results): |
View full study record |
Document reference: 24060 |
Study title: Benesch M et al Outcome and long-term side effects after synchronous radiochemotherapy forchildhood brain stem gliomas Pediatr Neurosurg. 2001 Oct;35(4):173-80Benesch M et al Outcome and long-term side effects after synchronous radiochemotherapy forchildhood brain stem gliomas Pediatr Neurosurg. 2001 Oct;35(4):173-80 |
Active substance: CYCLOPHOSPHAMIDE |
Study summary document link (including results): |
View full study record |
Document reference: 24766 |